Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.

Reaney M, Yu M, Lakshmanan M, Pechtner V, van Brunt K

Diabetes, obesity & metabolism27 Jul 2015Cited by 26 (Europe PMC)

PMID26095190DOI10.1111/dom.12527PepBankPUB-26095190

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In AWARD-1, both dulaglutide doses improved treatment satisfaction more than placebo.
In plain wordsIn AWARD-1, both dulaglutide doses improved treatment satisfaction more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAWARD-1 DTSQs versus placebo
Study
n: not reported in source
Comparator
placebo
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.5 mg and 0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The improvement was significantly greater with both dulaglutide doses compared with placebo (26 weeks) and exenatide (26 and 52 weeks).
2 context sentences(design, population, supporting numbers)
Summary · context
In the AWARD-1 study, significant improvements from baseline were observed in total DTSQs score for both dulaglutide doses (26 and 52 weeks) and exenatide (26 weeks).
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
Report a problemFND-2609519002
02HumanNon-randomized trialEfficacy outcome
In AWARD-1, both dulaglutide doses improved treatment satisfaction more than exenatide at 26 and 52 weeks.
In plain wordsIn AWARD-1, both dulaglutide doses improved treatment satisfaction more than exenatide at 26 and 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAWARD-1 DTSQs versus exenatide
Study
n: not reported in source
Comparator
exenatide
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.5 mg and 0.75 mg once weekly · 26 and 52 weeksAs given in this study (human).
Source sentences
Summary
The improvement was significantly greater with both dulaglutide doses compared with placebo (26 weeks) and exenatide (26 and 52 weeks).
2 context sentences(design, population, supporting numbers)
Summary · context
In the AWARD-1 study, significant improvements from baseline were observed in total DTSQs score for both dulaglutide doses (26 and 52 weeks) and exenatide (26 weeks).
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
Report a problemFND-2609519003
03HumanNon-randomized trialEfficacy outcome
In AWARD-1, both dulaglutide doses reduced perceived hyperglycaemia more than placebo.
In plain wordsIn AWARD-1, both dulaglutide doses reduced perceived high blood sugar more than placebo.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAWARD-1 perceived hyperglycaemia versus placebo
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg and 0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The improvement was greater with both dulaglutide doses and exenatide compared with placebo at 26 weeks, and was also greater with both dulaglutide doses compared with exenatide at 26 and 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The perceived frequency of hyperglycaemia was lower for all groups at 26 and 52 weeks compared with baseline.
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
Report a problemFND-2609519005
04HumanNon-randomized trialEfficacy outcome
In AWARD-1, both dulaglutide doses reduced perceived hyperglycaemia more than exenatide at 26 and 52 weeks.
In plain wordsIn AWARD-1, both dulaglutide doses reduced perceived high blood sugar more than exenatide at 26 and 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAWARD-1 perceived hyperglycaemia versus exenatide
Study
n: not reported in source
Comparator
exenatide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg and 0.75 mg once weekly · 26 and 52 weeksAs given in this study (human).
Source sentences
Summary
The improvement was greater with both dulaglutide doses and exenatide compared with placebo at 26 weeks, and was also greater with both dulaglutide doses compared with exenatide at 26 and 52 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The perceived frequency of hyperglycaemia was lower for all groups at 26 and 52 weeks compared with baseline.
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
Report a problemFND-2609519006
05HumanNon-randomized trialEfficacy outcome
In AWARD-3, both dulaglutide doses reduced perceived hyperglycaemia more than metformin at 52 weeks.
In plain wordsIn AWARD-3, both dulaglutide doses reduced perceived high blood sugar more than metformin at 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAWARD-3 perceived hyperglycaemia versus metformin
Study
n: not reported in source
Comparator
metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg and 0.75 mg once weekly · 52 weeksAs given in this study (human).
Source sentences
Summary
Perceived frequency of hyperglycaemia was lower for all groups at 26 and 52 weeks compared with baseline, and this improvement was greater with both dulaglutide doses compared with metformin at 52 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
Report a problemFND-2609519009

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In AWARD-1, treatment satisfaction improved from baseline with both dulaglutide doses at 26 and 52 weeks and exenatide at 26 weeks.
In plain wordsIn AWARD-1, satisfaction improved from baseline with both dulaglutide doses at 26 and 52 weeks and exenatide at 26 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAWARD-1 DTSQs
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Metabolic and weight
Source sentences
Summary
In the AWARD-1 study, significant improvements from baseline were observed in total DTSQs score for both dulaglutide doses (26 and 52 weeks) and exenatide (26 weeks).
1 context sentence(design, population, supporting numbers)
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2609519001
07HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In AWARD-1, perceived hyperglycaemia fell from baseline in all groups, including placebo, at 26 and 52 weeks.
In plain wordsIn AWARD-1, perceived high blood sugar fell from baseline in all groups, including placebo, at 26 and 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAWARD-1 perceived hyperglycaemia
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The perceived frequency of hyperglycaemia was lower for all groups at 26 and 52 weeks compared with baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2609519004
08HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In AWARD-3, treatment satisfaction improved from baseline in all groups, including metformin, at 26 and 52 weeks.
In plain wordsIn AWARD-3, treatment satisfaction improved from baseline in all groups, including metformin, at 26 and 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAWARD-3 DTSQs
Study
n: not reported in source
Outcome group
Patient-reported outcomes · Metabolic and weight
Source sentences
Summary
In the AWARD-3 study, significant improvements from baseline were observed for total DTSQs scores in all groups at 26 and 52 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2609519007
09HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome
In AWARD-3, perceived hyperglycaemia fell from baseline in all groups at 26 and 52 weeks.
In plain wordsIn AWARD-3, perceived high blood sugar fell from baseline in all groups at 26 and 52 weeks.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAWARD-3 perceived hyperglycaemia over time
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Perceived frequency of hyperglycaemia was lower for all groups at 26 and 52 weeks compared with baseline, and this improvement was greater with both dulaglutide doses compared with metformin at 52 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
To compare treatment satisfaction among people with type 2 diabetes receiving dulaglutide 1.5 mg and dulaglutide 0.75 mg (a once-weekly, long-acting, glucagon-like peptide-1 receptor agonist) with those receiving either exenatide or placebo (AWARD-1 study) or metformin (AWARD-3 study) over 52 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2609519008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.